Arca
Skip to content
Tools
Tools

KDM1A: Lysine-specific histone demethylase 1A

Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on KDM1A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 31

    • Bomedemstat

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        BomedemstatPhase 3Merck & Co. (MSD)Small moleculeInhibitorLysine-specific histone demethylase 1 inhibitor8

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).BomedemstatPhase 2 / Phase 3RecruitingMerck Sharp & Dohme LLCJul 23, 2026
        Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisBomedemstatPhase 2Not yet recruitingUnited Lincolnshire Hospitals NHS TrustFeb 20, 2026
        Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)BomedemstatPhase 3Active, not recruitingMerck Sharp & Dohme LLCJun 13, 2024
        A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)BomedemstatPhase 3RecruitingMerck Sharp & Dohme LLCApr 8, 2024
        A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)BomedemstatPhase 3Active, not recruitingMerck Sharp & Dohme LLCOct 12, 2023
        Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaBomedemstatPhase 1RecruitingTerrence J Bradley, MDOct 28, 2022
        IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)BomedemstatPhase 2Active, not recruitingTerrence J Bradley, MDFeb 10, 2020
        Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2BomedemstatPhase 2Active, not recruitingThe University of Texas Health Science Center at San AntonioSep 9, 2019

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome0.73
        • Neurodegenerative disease0.55
        • ACTH-independent macronodular adrenal hyperplasia 30.47
        • Global developmental delay0.40
        • Cushing syndrome due to macronodular adrenal hyperplasia0.38
        • Intellectual disability0.30
        • Neurodevelopmental delay0.27
        • Plasma cell myeloma0.20
        • AL amyloidosis0.20
        • Hereditary disease0.20
        • Lysosomal storage disease0.18

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL6136, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O60341, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.